"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
Hypersensitivity Reactions: Case series report an overall incidence of hypersensitivity reactions in approximately 2% of patients. Life- threatening anaphylactic reactions have occurred. Manifestations include respiratory distress, shock, angioedema, urticaria, pruritus. A death has been reported following administration of a similar compound employed to estimate the depth of a severe burn. Reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, drug reactions or previous reactions to triphenylmethane dyes [see WARNINGS and PRECAUTIONS].
Skin: transient or long-term (tattooing) blue coloration.
Read the Lymphazurin (isosulfan blue) Side Effects Center for a complete guide to possible side effects
No drug interactions have been identified with Lymphazurin (isosulfan blue) 1%.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/13/2008
Additional Lymphazurin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.